Arcellx (NASDAQ:ACLX) Downgraded to Hold Rating by Evercore

Arcellx (NASDAQ:ACLX) was downgraded by Evercore from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. UBS Group lowered shares of Arcellx from a “buy” rating to a “neutral” rating and upped their price objective for the company from $100.00 to $115.00 in a research note on Tuesday. Robert W. Baird reaffirmed a “neutral” rating and set a $115.00 price target (up from $106.00) on shares of Arcellx in a research report on Monday. Rothschild & Co Redburn lowered Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price objective for the company. in a research report on Thursday, February 12th. Wells Fargo & Company downgraded Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Arcellx presently has an average rating of “Hold” and an average price target of $111.64.

Arcellx Price Performance

Arcellx stock opened at $113.71 on Monday. The stock’s 50 day moving average is $68.84 and its 200 day moving average is $75.38. Arcellx has a one year low of $47.86 and a one year high of $114.26. The firm has a market cap of $6.57 billion, a P/E ratio of -28.93 and a beta of 0.36.

Insider Activity

In other news, insider Christopher Heery sold 7,437 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total value of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares in the company, valued at $1,941,126.81. This trade represents a 20.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MAI Capital Management bought a new stake in shares of Arcellx during the third quarter valued at approximately $26,000. CWM LLC grew its position in Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after purchasing an additional 251 shares during the period. State of Wyoming bought a new stake in Arcellx during the 2nd quarter valued at $28,000. Ramirez Asset Management Inc. bought a new stake in Arcellx during the 3rd quarter valued at $41,000. Finally, Abich Financial Wealth Management LLC acquired a new position in Arcellx during the third quarter worth $62,000. Institutional investors own 96.03% of the company’s stock.

Key Stories Impacting Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.